HER2 inhibition: from discovery to clinical practice.
Chang
Jenny C
JC
Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA. jcchang@breastcenter.tmc.edu
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D019281:Dimerization; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008954:Models, Biological; D011487:Protein Conformation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab